About
In2Cell is an early-stage company building POLEX, a platform that reads a drug's impact directly on the tumour genome. Instead of dosing by protocol and hope, POLEX shows whether a treatment is actually reaching the tumour, so patients aren't blindsided by a drug that was never going to work.
Precise cancer care, without the guesswork.
A future where no cancer drug is given blind, and every patient's treatment is guided by what is actually happening in their tumour.